United States - English - NLM (National Library of Medicine)

immunex corporation - etanercept (unii: op401g7ojc) (etanercept - unii:op401g7ojc) - etanercept 50 mg in 1 ml - enbrel is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis (ra). enbrel can be initiated in combination with methotrexate (mtx) or used alone. enbrel is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (pjia) in patients 2 years of age and older. enbrel is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in adult patients with psoriatic arthritis (psa). enbrel can be used with or without methotrexate. enbrel is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis (as). enbrel is indicated for the treatment of patients 4 years or older with chronic moderate to severe plaque psoriasis (pso) who are candidates for systemic therapy or photo

Australia - English - Department of Health (Therapeutic Goods Administration)

samsung bioepis au pty ltd - etanercept, quantity: 50 mg - injection, solution - excipient ingredients: water for injections; monobasic sodium phosphate monohydrate; sodium chloride; dibasic sodium phosphate heptahydrate; sucrose - adults (18 years and older),rheumatoid arthritis,active, adult rheumatoid arthritis (ra) in patients who have had inadequate response to one or more disease-modifying antirheumatic drugs (dmards). brenzys can be used in combination with methotrexate. severe, active rheumatoid arthritis in adults to slow progression of disease-associated structural damage in patients at high risk of erosive disease.,psoriatic arthritis,the signs and symptoms of active and progressive psoriatic arthritis in adults, when the response to previous disease-modifying antirheumatic therapy has been inadequate. etanercept has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function.,plaque psoriasis,adult patients with moderate to severe chronic plaque psoriasis, who are candidates for phototherapy or systemic therapy.,ankylosing spondylitis,the signs and symptoms of active ankylosing spondylitis in adults.,non-radiographic axial spondyloarthritis,treatment of adults with active* non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or mri change who have had an inadequate response to nsaids .,*active disease is defined as a bath ankylosing spondylitis disease activity index (basdai) score of greater than or equal to 4.

Australia - English - Department of Health (Therapeutic Goods Administration)

samsung bioepis au pty ltd - etanercept, quantity: 50 mg - injection, solution - excipient ingredients: monobasic sodium phosphate monohydrate; dibasic sodium phosphate heptahydrate; sodium chloride; sucrose; water for injections - adults (18 years and older),rheumatoid arthritis,active, adult rheumatoid arthritis (ra) in patients who have had inadequate response to one or more disease-modifying antirheumatic drugs (dmards). brenzys can be used in combination with methotrexate. severe, active rheumatoid arthritis in adults to slow progression of disease-associated structural damage in patients at high risk of erosive disease.,psoriatic arthritis,the signs and symptoms of active and progressive psoriatic arthritis in adults, when the response to previous disease-modifying antirheumatic therapy has been inadequate. etanercept has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function.,plaque psoriasis,adult patients with moderate to severe chronic plaque psoriasis, who are candidates for phototherapy or systemic therapy.,ankylosing spondylitis,the signs and symptoms of active ankylosing spondylitis in adults.,non-radiographic axial spondyloarthritis,treatment of adults with active* non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or mri change who have had an inadequate response to nsaids .,*active disease is defined as a bath ankylosing spondylitis disease activity index (basdai) score of greater than or equal to 4.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - etanercept, quantity: 50 mg - injection, solution - excipient ingredients: sucrose; monobasic sodium phosphate dihydrate; sodium chloride; water for injections; dibasic sodium phosphate dihydrate; arginine hydrochloride - enbrel is indicated for the treatment of: adults rheumatoid arthritis active, adult rheumatoid arthritis (ra) in patients who have had inadequate response to one or more disease-modifying antirheumatic drugs (dmards). enbrel can be used in combination with methotrexate. severe, active rheumatoid arthritis in adults to slow progression of disease-associated structural damage in patients at high risk of erosive disease. psoriatic arthritis the signs and symptoms of active and progressive psoriatic arthritis in adults, when the response to previous disease-modifying antirheumatic therapy has been inadequate. enbrel has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function. plaque psoriasis adult patients with moderate to severe chronic plaque psoriasis, who are candidates for phototherapy or systemic therapy. ankylosing spondylitis the signs and symptoms of active ankylosing spondylitis in adults. non-radiographic axial spondyloarthritis treatment of a

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - etanercept, quantity: 50 mg - injection, solution - excipient ingredients: sodium chloride; water for injections; monobasic sodium phosphate dihydrate; dibasic sodium phosphate dihydrate; arginine hydrochloride; sucrose - enbrel is indicated for the treatment of: adults rheumatoid arthritis active, adult rheumatoid arthritis (ra) in patients who have had inadequate response to one or more disease-modifying antirheumatic drugs (dmards). enbrel can be used in combination with methotrexate. severe, active rheumatoid arthritis in adults to slow progression of disease-associated structural damage in patients at high risk of erosive disease. psoriatic arthritis the signs and symptoms of active and progressive psoriatic arthritis in adults, when the response to previous disease-modifying antirheumatic therapy has been inadequate. enbrel has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function. plaque psoriasis adult patients with moderate to severe chronic plaque psoriasis, who are candidates for phototherapy or systemic therapy. ankylosing spondylitis the signs and symptoms of active ankylosing spondylitis in adults. non-radiographic axial spondyloarthritis treatment of a

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

nichi-iko pharmaceutical co.,ltd - etanercept (genetical recombination) [etanercept biosimilar 2] - colorless to pale yellow and limpid injectable preparation in a syringe

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

teijin pharma limited - etanercept (genetical recombination)[etanercept biosimilar 2] - colorless to pale yellow and limpid injectable preparation in syringe

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

ayumi pharmaceutical co., ltd. - etanercept (genetical recombination)[etanercept biosimilar 1] - white freeze-dry powder injectable preparation

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

nichi-iko pharmaceutical co.,ltd - etanercept (genetical recombination) [etanercept biosimilar 2] - colorless to pale yellow and limpid injectable preparation in a syringe

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

teijin pharma limited - etanercept (genetical recombination)[etanercept biosimilar 2] - colorless to limpid pale yellow injectable preparation in syringe